XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2025 USD ($)
Disaggregation of Revenue [Line Items] |
Percentage share of profits to reimburse collaborating party | 20.00%
Contingent reimbursement obligation | $ 1,453
Starting share of profits outside the United States, based on sales, for collaborating party | 65.00%
Starting share of profits outside the United States, based on sales, for Company | 35.00%
Ending share of profits outside the United States, based on sales, for collaborating party | 55.00%
Ending share of profits outside the United States, based on sales, for Company | 45.00%
Minimum |
Disaggregation of Revenue [Line Items] |
Percentage of trial costs required to be funded by collaborating party | 80.00%
Percentage share of profits to reimburse collaborating party | 30.00%
Maximum |
Disaggregation of Revenue [Line Items] |
Percentage of trial costs required to be funded by collaborating party | 100.00%
Percentage share of profits to reimburse collaborating party | 50.00%

X
- Definition The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner. + References No definition available. + Details
Name: | regn_ContingentReimbursementObligation
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party. + References No definition available. + Details
Name: | regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company. + References No definition available. + Details
Name: | regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs + References No definition available. + Details
Name: | regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Trial Costs Required To Be Funded By Collaborating Party + References No definition available. + Details
Name: | regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party. + References No definition available. + Details
Name: | regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company. + References No definition available. + Details
Name: | regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
Namespace Prefix: | regn_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |